High-content CRISPR screening in tumor immunology

Erin A. Holcomb; Erin A. Holcomb; Ashley  N. Pearson; Ashley  N. Pearson; Kassidy M. Jungles; Kassidy M. Jungles; Kassidy M. Jungles; Akshay Tate; Jadyn James; Long Jiang; Long Jiang; Amanda  K. Huber; Michael D. Green; Michael D. Green; Michael D. Green; Michael D. Green; Michael D. Green

doi:10.3389/fimmu.2022.1041451

Frontiers in Immunology (Nov 2022)

High-content CRISPR screening in tumor immunology

Erin A. Holcomb,
Erin A. Holcomb,
Ashley N. Pearson,
Ashley N. Pearson,
Kassidy M. Jungles,
Kassidy M. Jungles,
Kassidy M. Jungles,
Akshay Tate,
Jadyn James,
Long Jiang,
Long Jiang,
Amanda K. Huber,
Michael D. Green,
Michael D. Green,
Michael D. Green,
Michael D. Green,
Michael D. Green

Affiliations

Erin A. Holcomb: Graduate Program in Immunology, School of Medicine, University of Michigan, Ann Arbor, MI, United States
Erin A. Holcomb: Department of Radiation Oncology, School of Medicine, University of Michigan, Ann Arbor, MI, United States
Ashley N. Pearson: Graduate Program in Immunology, School of Medicine, University of Michigan, Ann Arbor, MI, United States
Ashley N. Pearson: Department of Radiation Oncology, School of Medicine, University of Michigan, Ann Arbor, MI, United States
Kassidy M. Jungles: Department of Radiation Oncology, School of Medicine, University of Michigan, Ann Arbor, MI, United States
Kassidy M. Jungles: Department of Pharmacology, School of Medicine, University of Michigan, Ann Arbor, MI, United States
Kassidy M. Jungles: Rogel Cancer Center, University of Michigan, Ann Arbor, MI, United States
Akshay Tate: Department of Radiation Oncology, School of Medicine, University of Michigan, Ann Arbor, MI, United States
Jadyn James: Department of Radiation Oncology, School of Medicine, University of Michigan, Ann Arbor, MI, United States
Long Jiang: Department of Radiation Oncology, School of Medicine, University of Michigan, Ann Arbor, MI, United States
Long Jiang: Institute of Health and Medicine, Hefei Comprehensive National Science Center, Hefei, China
Amanda K. Huber: Department of Radiation Oncology, School of Medicine, University of Michigan, Ann Arbor, MI, United States
Michael D. Green: Graduate Program in Immunology, School of Medicine, University of Michigan, Ann Arbor, MI, United States
Michael D. Green: Department of Radiation Oncology, School of Medicine, University of Michigan, Ann Arbor, MI, United States
Michael D. Green: Rogel Cancer Center, University of Michigan, Ann Arbor, MI, United States
Michael D. Green: Department of Microbiology and Immunology, School of Medicine, University of Michigan, Ann Arbor, MI, United States
Michael D. Green: Department of Radiation Oncology, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, MI, United States

DOI: https://doi.org/10.3389/fimmu.2022.1041451
Journal volume & issue: Vol. 13

Abstract

Read online

CRISPR screening is a powerful tool that links specific genetic alterations to corresponding phenotypes, thus allowing for high-throughput identification of novel gene functions. Pooled CRISPR screens have enabled discovery of innate and adaptive immune response regulators in the setting of viral infection and cancer. Emerging methods couple pooled CRISPR screens with parallel high-content readouts at the transcriptomic, epigenetic, proteomic, and optical levels. These approaches are illuminating cancer immune evasion mechanisms as well as nominating novel targets that augment T cell activation, increase T cell infiltration into tumors, and promote enhanced T cell cytotoxicity. This review details recent methodological advances in high-content CRISPR screens and highlights the impact this technology is having on tumor immunology.

Published in Frontiers in Immunology

ISSN: 1664-3224 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
Website: http://journal.frontiersin.org/journal/immunology

About the journal

Abstract

Keywords